Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
Previous Symbol
CUSIPN/A
Phone44-20-3283-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.13
Quick Ratio7.13
Price-To-Earnings
Trailing P/E Ratio-4.68
Forward P/E Ratio-5.33
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.84 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-34.31%
Return on Assets-28.83%
Miscellaneous
Employees15
Outstanding Shares13,130,000
Market Cap$145.32 million
OptionableNot Optionable
VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions
What is VERONA PHARMA P/S's stock symbol?
VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."
How were VERONA PHARMA P/S's earnings last quarter?
VERONA PHARMA P/S (NASDAQ:VRNA) announced its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.49) by $0.26. View VERONA PHARMA P/S's Earnings History.
When is VERONA PHARMA P/S's next earnings date?
What price target have analysts set for VRNA?
5 brokers have issued twelve-month price targets for VERONA PHARMA P/S's shares. Their predictions range from $25.00 to $56.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $34.80 in the next year. This suggests a possible upside of 208.2% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.
What is the consensus analysts' recommendation for VERONA PHARMA P/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.
What are Wall Street analysts saying about VERONA PHARMA P/S stock?
Here are some recent quotes from research analysts about VERONA PHARMA P/S stock:
- 1. According to Zacks Investment Research, "Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. " (11/10/2018)
- 2. Wedbush analysts commented, "We reiterate our Buy rating for Jazz Pharmaceuticals plc (JAZZ), our top pick and Alpha Generator, with our $219 PT. We see attractive valuation for JAZZ shares at 12.3x our 2018E EPS estimate of $13.15 and 10.4x our 2019E EPS estimate of $15.65. Jazz held a webcast update for its Vyxeos EU launch on and we highlight takeaways. First, the EU is nearly as key as the US market with an estimated 20,000 diagnosed AML leukemia cases annually with drug treated cases representing 10,000 and about 8,000 patients excluding clinical trials. The EU AML population that coincides with the label is about 3,000-4,000." (9/19/2018)
Has VERONA PHARMA P/S been receiving favorable news coverage?
Headlines about VRNA stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. VERONA PHARMA P/S earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the next few days.
Who are some of VERONA PHARMA P/S's key competitors?
Some companies that are related to VERONA PHARMA P/S include Collegium Pharmaceutical (COLL), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Ra Pharmaceuticals (RARX), Basilea Pharmaceutica (BPMUF), Arvinas (ARVN), Insys Therapeutics (INSY), Eidos Therapeutics (EIDX), Arcus Biosciences (RCUS), GlycoMimetics (GLYC), ChemoCentryx (CCXI), Innate Pharma (IPHYF), Clementia Pharmaceuticals (CMTA), Kezar Life Sciences (KZR) and Beyondspring (BYSI).
Who are VERONA PHARMA P/S's key executives?
VERONA PHARMA P/S's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 56)
- Mr. Richard Hennings, Commercial Director (Age 48)
When did VERONA PHARMA P/S IPO?
(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
Who are VERONA PHARMA P/S's major shareholders?
VERONA PHARMA P/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Foresite Capital Management IV LLC (0.06%).
Which institutional investors are buying VERONA PHARMA P/S stock?
VRNA stock was acquired by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC.
How do I buy shares of VERONA PHARMA P/S?
Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VERONA PHARMA P/S's stock price today?
One share of VRNA stock can currently be purchased for approximately $11.2902.
How big of a company is VERONA PHARMA P/S?
VERONA PHARMA P/S has a market capitalization of $145.32 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. VERONA PHARMA P/S employs 15 workers across the globe.
What is VERONA PHARMA P/S's official website?
How can I contact VERONA PHARMA P/S?
VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]
MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
